Envestnet Asset Management Inc. Has $2.23 Million Position in DaVita Inc. (NYSE:DVA)

Envestnet Asset Management Inc. lowered its position in shares of DaVita Inc. (NYSE:DVA – Get Rating) by 32.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,899 shares of the company’s stock after selling 14,575 shares during the quarter. Envestnet Asset Management Inc.’s holdings in DaVita were worth $2,233,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of DVA. Raymond James & Associates lifted its holdings in shares of DaVita by 4.0% in the first quarter. Raymond James & Associates now owns 22,651 shares of the company’s stock valued at $2,562,000 after purchasing an additional 865 shares in the last quarter. American Century Companies Inc. raised its position in DaVita by 37.4% in the 1st quarter. American Century Companies Inc. now owns 6,555 shares of the company’s stock valued at $741,000 after buying an additional 1,785 shares during the last quarter. US Bancorp DE raised its position in DaVita by 63.6% in the 1st quarter. US Bancorp DE now owns 2,998 shares of the company’s stock valued at $338,000 after buying an additional 1,166 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its position in DaVita by 7.3% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 3,551 shares of the company’s stock valued at $402,000 after buying an additional 242 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its position in DaVita by 847.8% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,090 shares of the company’s stock valued at $123,000 after buying an additional 975 shares during the last quarter. Institutional investors and hedge funds own 86.52% of the company’s stock.

DaVita Stock Performance

DVA opened at $100.33 on Friday. The business has a fifty day simple moving average of $85.34 and a 200 day simple moving average of $79.78. The company has a market capitalization of $9.10 billion, a PE ratio of 18.51, a price-to-earnings-growth ratio of 1.01 and a beta of 0.93. DaVita Inc. has a 1 year low of $65.28 and a 1 year high of $103.00. The company has a debt-to-equity ratio of 8.25, a current ratio of 1.18 and a quick ratio of 1.14.

DaVita (NYSE:DVA – Get Rating) last released its quarterly earnings results on Monday, May 8th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.50. The business had revenue of $2.87 billion during the quarter, compared to the consensus estimate of $2.84 billion. DaVita had a return on equity of 72.08% and a net margin of 4.40%. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.61 EPS. Research analysts expect that DaVita Inc. will post 6.72 EPS for the current year.

Insider Activity at DaVita

In related news, Director Phyllis R. Yale sold 2,196 shares of the business’s stock in a transaction on Friday, May 12th. The stock was sold at an average price of $95.26, for a total value of $209,190.96. Following the completion of the sale, the director now directly owns 13,110 shares in the company, valued at approximately $1,248,858.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other DaVita news, Director Charles Berg sold 735 shares of DaVita stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $81.78, for a total value of $60,108.30. Following the completion of the transaction, the director now directly owns 17,164 shares of the company’s stock, valued at approximately $1,403,671.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Phyllis R. Yale sold 2,196 shares of DaVita stock in a transaction on Friday, May 12th. The shares were sold at an average price of $95.26, for a total value of $209,190.96. Following the completion of the transaction, the director now directly owns 13,110 shares of the company’s stock, valued at $1,248,858.60. The disclosure for this sale can be found here. Insiders sold 39,668 shares of company stock worth $3,889,765 in the last ninety days. 1.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. UBS Group lifted their target price on DaVita from $91.00 to $100.00 in a research report on Tuesday, May 9th. TheStreet upgraded DaVita from a “c” rating to a “b-” rating in a research note on Monday, May 8th. StockNews.com began coverage on DaVita in a research note on Thursday. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft raised their price target on DaVita from $85.00 to $113.00 in a research note on Tuesday, May 9th. Finally, Truist Financial raised their price target on DaVita from $90.00 to $100.00 in a research note on Tuesday, May 9th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, DaVita currently has a consensus rating of “Hold” and an average target price of $96.88.

DaVita Company Profile

(Get Rating)

DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.